Biomedical Engineering Reference
In-Depth Information
[182] Dong L, Xia S, Chen H, Chen J, Zhang J. Spleen-specific suppression of TNF- by cat-
ionic hydrogel-delivered antisense nucleotides for the prevention of arthritis in animal
models. Biomaterials 2009;30:4416-26.
[183] Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug
delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev 2002;
54:135-47.
[184] Sud T, Li D. Hydrodynamic gene delivery: its principles and applications. Mol Ther
2007;15:2063-9.
[185] Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, et al. Reduction in
connective tissue growth factor by antisense treatment ameliorates renal tubulointersti-
tial fibrosis. J Am Soc Nephrol 2004;15:1430-40.
[186] Bergan R, Connell Y, Fahmy B, Neckers L. Electroporation enhances c-myc antisense
oligodeoxynucleotide efficacy. Nucleic Acids Res 1993;21:3567-73.
[187] Zewert TE, Pliquett UF, Langer R, Weaver JC. Transdermal transport of DNA antisense
oligonucleotides by electroporation. Biochem Biophys Res Commun 1995;212:286-92.
[188] Gravas S, Mamoulakis C, Rioja J, Tzortzis V, Reijke T, Wijkstra H, et al. Advances in
ultrasound technology in oncologic urology. Urol Clin North Am 2009;36:133-45.
[189] Haag P, Frauscher F, Gradl J, Seitz A, Schafer G, Lindner JR, et al. Microbubble-enhanced
ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen
receptor into prostate tumours. J Steroid Biochem Mol Biol 2006;102:103-13.
[190] Casey JP, Blidner RA, Monroe WT. Caged siRNAs for spatiotemporal control of gene
silencing. Mol Pharm 2009;6:669-85.
[191] Zavaglia D, Normand N, Brewis N, O'Hare P, Favrot MC, Coll J. VP22-mediated and
light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity
after intratumoral injection in nude mice. Mol Ther 2003;8:840-5.
[192] Kaplan JH, Forbush B, Hoffman JF. Rapid photolytic release of adenosine 5-triphos-
phate from a protected analog—utilization by na-k pump of human red blood-cell
ghosts. Biochemistry 1978;17:1929-35.
[193] Young DD, Lusic H, Lively MO, Yoder JA, Deiters A. Gene silencing in mammalian
cells with light-activated antisense agents. Chem Bio Chem 2008;9:2937-40.
[194] Brink PR. Stem cells as a non-immunogenic vehicle for delivery of siRNA. Third
Annual RNAi for Developing Targeted Therapeutics, November 2-3, 2009, Boston
Massachusetts.
[195] Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJ, et al.
siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004;32:e49.
[196] Schiffelers RM, Xu J, Storm G, Woodle MC, Scaria PV. Effects of treatment with small
interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis
Rheum. 2005;52:1314-18.
[197] Barclay J, Patel S, Dorn G, Wotherspoon G, Moffatt S, Eunson L, et al. Functional
downregulation of P2X3 receptor subunit in rat sensory neurons reveals a significant
role in chronic neuropathic and inflammatory pain. J Neurosci 2004;22:8139-47.
[198] Thakker DR, Natt F, Husken D, van der Putten H, Maier R, Hoyer D, et al. siRNA-
mediated knockdown of the serotonin transporter in the adult mouse brain. Mol
Psychiatry 2005;10:782-9.
[199] Bochot A, Couvreur P, Fattal E. Intavitreal administration of antisense oligonucleotides:
potential of liposomal delivery. Prog Retin Eye Res 2000;19:131-47.
[200] Reich S, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, et al. Small interfering
RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse
model. Mol Vis 2003;30:210-16.
Search WWH ::
Custom Search